| Active Ingredient | ATRACURIUM |
| Therapeutic Class | NEUROMUSCULAR BLOCKING AGENTS |
| Indications | Neuromuscular blockade (short to intermediate duration) for surgery and intubation. |
| Caution | Flushing; hypotension,Bronchospasm; hypersensitivity; skin reactions; tachycardia. |
| Dose Range | Initially 300–600 micrograms/kg, then (by intravenous injection) 100–200 micrograms/kg as required, alternatively (by intravenous injection) initially 300–600 micrograms/kg, followed by (by intravenous infusion) 300–600 micrograms/kg/hour. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | CISATRACURIUM |
| Therapeutic Class | NEUROMUSCULAR BLOCKING AGENTS |
| Indications | Neuromuscular blockade. |
| Caution | Bradycardia. |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding | Discontinue breastfeeding until the mother has recovered from neuromuscular bloc More ... |
| Active Ingredient | PANCURONIUM BROMIDE |
| Therapeutic Class | NEUROMUSCULAR BLOCKING AGENTS |
| Indications | Usual drug of choice for major surgery and for use with long term ventilation of intensive care patients. |
| Caution |
Caution in hepatic and renal impairment. C.f. prescribing in renal disease p. 34. |
| Dose Range | i.v. 0.05-0.1mg/kg, then 0.01-0.02mg/kg as required. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding | Discontinue breastfeeding until the mother has recovered from neuromuscular bloc More ... |
| Active Ingredient | SUXAMETHONIUM |
| Therapeutic Class | NEUROMUSCULAR BLOCKING AGENTS |
| Indications | Depolarising muscle relaxant of short duration (about 5 mins). Useful for endotracheal intubation |
| Caution | Tachycardia, apnoea, flushing. |
| Dose Range |
Adults and children: i.v. 0.5-2mg/kg dep ending on degree of relaxation required. c.f. prescribing in liver disease p. 18. |
| Drug Interactions | |
| Pregnancy | Mildly prolonged maternal neuromuscular blockade may occur. |
| Breast Feeding | Discontinue breastfeeding until the mother has recovered from neuromuscular bloc More ... |
| Active Ingredient | TIZANIDINE |
| Therapeutic Class | NEUROMUSCULAR BLOCKING AGENTS |
| Indications | Spasticity associated with multiple sclerosis and cerebrovascular or spinal cord disorders. |
| Caution | Drowsiness, muscle weakness, dry mouth, fatigue, insomnia, G.I. disturbances, dizziness. |
| Dose Range | Adult: 2-4mg three times daily . Maximum dose is 36mg daily. Safety has not been determined in children.See BDS supply protocols pg. 11. |
| Drug Interactions | |
| Pregnancy | Avoid Tizanidine during pregnancy. |
| Breast Feeding | Avoid breastfeeding during Tizanidine therapy. |